By: Jax DiEugenio From: onclive.com Following the publication of the KATHERINE trial (NCT01772472), a number of novel clinical trials have emerged with the use of antibody-drug conjugates (ADCs), checkpoint inhibitors, and TKIs aimed at further improving outcomes for patients with high-risk, early-stage HER2-positive breast cancer, according to Paolo Tarantino, MD. In the second part of an interview with OncLive®, Tarantino …
Development of Novel HER2-Targeted Therapies Could Help Reshape Treatment for HER2+ Breast Cancer
By: Jax DiEugenio From: onclive.com Fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) and other novel antibody-drug conjugates (ADCs) currently under development have represented key change in the treatment landscape for HER2-positive breast cancer, and other novel HER2-targeted therapies could also bring further change to the space, according to Kelly E. McCann, MD, PhD. “We have to think about how can we optimize care …
Systemic Therapies Are Now Preferred in Some Patients With HER2+ Breast Cancer Brain Metastases
By: Silas Inman From: onclive.com The high level of intracranial activity seen with novel HER2-targeted therapies has created a new paradigm that defers local therapy in favor of systemic options to treat small asymptomatic brain metastases in patients with metastatic breast cancer, explained Sara A. Hurvitz, MD, FACP, at the 42nd Annual Miami Breast Cancer Conference.1 The newer agents that …
Neoadjuvant Atezolizumab/Trastuzumab/Pertuzumab Is Effective and Safe in HER2+ Early Breast Cancer
By: vAshling Wahner From: .onclive.com Key Takeaways Neoadjuvant atezolizumab with dual HER2 blockade and epirubicin achieved a 60.3% pCR rate in early HER2-positive breast cancer patients. The trial highlighted potential benefits of chemotherapy de-escalation and ICIs, despite mixed results in previous studies. Limitations included small sample size, absence of a non-ICI arm, and lack of long-term outcomes, prompting further research …
Central Nervous System Disease Drives Mortality in HER2+ Metastatic Breast Cancer Despite Longer Survival
By: Alexandra Gerlach From: .pharmacytimes.com Key Takeaways HER2+ MBC patients with CNS disease have longer overall survival than those with extracranial metastasis. CNS metastases in HER2+ breast cancer remain difficult to treat, requiring local therapies like radiotherapy. CNS progression is a major mortality cause in HER2+ MBC, highlighting the need for CNS-penetrant therapies. Clinical trials should include CNS disease patients …
FDA Accepts BLA for Pertuzumab Biosimilar in HER2+ Breast Cancer
By: Chris Ryan From: onclive.com Key Takeaways HLX11, a pertuzumab biosimilar, is under FDA review for HER2-positive breast cancer treatment, supported by phase 1 and phase 3 trial data. Phase 1 trial confirmed pharmacokinetic equivalence and similar safety profiles between HLX11 and pertuzumab, with no impact from anti-drug antibodies. Phase 3 trial showed HLX11’s efficacy in achieving comparable pathological complete …
How Combining Drugs May Be More Effective at Treating HER2-Positive Breast Cancer
By: Tayler Shaw From: cuanschutz.edu When oncologist Elena Shagisultanova, MD, PhD, joined the University of Colorado Anschutz Medical Campus in 2015, she started working in a clinic to help young women with breast cancer. She soon noticed that certain types of breast cancer — called HER2-positive and HR-positive — were more common than expected. “I felt right away that the …
New insights in breast cancer progression and drug resistance
Source: University of Liverpool From: eurekalert.org A significant breakthrough in breast cancer research has uncovered a key mechanism driving cancer invasion and drug resistance. A University of Liverpool study reveals how two critical molecules present in ‘HER2-positive’ breast cancer – one of the most aggressive forms – influence breast cancer survival and its spread. These proteins, HER2 and αVβ6 integrin, …
IBI354 Shows Efficacy and Safety in HER2+ and HER2-Low Advanced Breast Cancer
Author: Jax DiEugenio From: onclive.com Key Takeaways IBI354 demonstrated significant efficacy in HER2-positive and HER2-low breast cancer, with ORRs of 67.8% and 41.8%, respectively. The phase 1 study included dose-escalation and dose-expansion phases, with no dose-limiting toxicities observed up to 18 mg/kg. The safety profile of IBI354 was favorable, with mild treatment-related adverse effects, including nausea and decreased blood cell …
HER2-Positive Breast Cancer Diet
From: healthline.com Foods such as sugar, saturated fats, and alcohol may promote the spread of HER2-positive breast cancer and should be avoided if you have this cancer. Some other foods may slow the cancer’s progress. Can diet help HER2-positive breast cancer? Your daily diet can affect your overall health. About 18% of all cancersTrusted Source may be related to diet, …